Examining the Mechanisms of the Investigational Antipsychotic, KarXT

Time: 2:15 pm
day: Day Two


  • Unveiling KarXT (xanomeline + trospium); an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease
  • Harnessing research which indicates that activity at M1 and M4 receptors indirectly affects dopamine neurotransmission in brain regions involved in mediating symptoms of serious mental illness, such as psychosis in Alzheimer’s disease, as well as the positive, negative, and cognitive symptoms of schizophrenia
  • Centrally active xanomeline has demonstrated unique agonistic pharmacology at the muscarinic receptors including persistent binding and functional selectivity based on cryo-EM, molecular dynamics, and mutagenesis experiments